June 10, 2014
/PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Wells Fargo 2014 Healthcare Conference in
The presentation at the Wells Fargo conference is scheduled for
3:35 pm ET
12:35 pm PT
Wednesday June 18
, 2014. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at
. A recording of the webcast will be archived for 30 days on the company's website.
Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Gralise
(gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA
(diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor
(diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda
(fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform
drug delivery technology. Additional information about Depomed may be found at
INVESTOR CONTACT:August J. Moretti Depomed, Inc. 510.744.8000
SOURCE Depomed, Inc.